Genotyping external quality assurance in the world health organization HIV drug resistance laboratory network during 2007-2010

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Parkin, Neil ^a,c   Bremer, James ^b   Bertagnolio, Silvia ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b RUSH UNIVERSITY   (United States)

^c DATA FIRST CONSULTING INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ASIA; CENTRAL AMERICA; CONTROLLED STUDY; GENE MUTATION; GENOTYPING TECHNIQUE; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; LABORATORY TEST; NONHUMAN; NORTH AMERICA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RELIABILITY; REVIEW; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HIV; HIV INFECTIONS; HUMANS; LABORATORIES; LABORATORY PROFICIENCY TESTING; POPULATION SURVEILLANCE; REPRODUCIBILITY OF RESULTS; VIROLOGY; WORLD HEALTH ORGANIZATION;

EID: 84860375551     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir992     Document Type: Review

References (20)

1. World Health Organization, Joint United Nations Program on HIV/AIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva, Switzerland: World Health Organization, 2010. Available at: http://www.who.int/hiv/pub/2010progressreport/en/index.html. Accessed 5 July 2011.
2. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13. (Pubitemid 352019085)
3. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Organization/HIVResNet drug resistance laboratory strategy. Antivir Ther 2008; 13(Suppl 2):49-57. (Pubitemid 352019089)
4. Galli RA, Sattha B, Wynhoven B, O'Shaughnessy MV, Harrigan PR. Sources and magnitude of intralaboratory variability in a sequencebased genotypic assay for human immunodeficiency virus type 1 drug resistance. J Clin Microbiol 2003; 41:2900-7. (Pubitemid 36842277)
5. Huang DD, Eshleman SH, Brambilla DJ, Palumbo PE, Bremer JW. Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J Clin Microbiol 2003; 41:3265-72. (Pubitemid 36842332)
6. Korn K, Reil H, Walter H, Schmidt B. Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol 2003; 41:3559-65. (Pubitemid 36994682)
7. Neuwald PD, Funelas MB, DelCarmen JP, Raybold AW, Jorgensen PA. Results of the 2001 AcroMetrix HIV-1 resistance proficiency program. J Clin Virol 2002; 25(Suppl 3):S55-63. (Pubitemid 35441016)
8. Sayer DC, Land S, Gizzarelli L, et al. Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. J Clin Microbiol 2003; 41:227-36. (Pubitemid 36098581)
9. Schuurman R, Brambilla D, de Groot T, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 2002; 18:243-8. (Pubitemid 34253141)
10. Descamps D, Delaugerre C, Masquelier B, et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78:153-60. (Pubitemid 43132558)
11. Huang DD, Bremer JW, Brambilla DJ, et al. Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays. J Clin Microbiol 2005; 43:3963-70. (Pubitemid 41129687)
12. Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuay L. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol 1992; 30:1787-94.
13. Huang DD, Giesler TA, Bremer JW. Sequence characterization of the protease and partial reverse transcriptase proteins of the NED panel, an international HIV type 1 subtype reference and standards panel. AIDS Res Hum Retroviruses 2003; 19:321-8. (Pubitemid 36458225)
14. Eshleman SH, Crutcher G, Petrauskene O, et al. Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J Clin Microbiol 2005; 43:813-7. (Pubitemid 40256039)
15. Grant RM, Kuritzkes DR, Johnson VA, et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003; 41:1586-93. (Pubitemid 36428108)
16. Kuritzkes DR, Grant RM, Feorino P, et al. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol 2003; 41:1594-9. (Pubitemid 36428109)
17. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17:138-45.
18. Hallack R, Doherty LE, Wethers JA, Parker MM. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J Clin Virol 2008; 41:283-7.
19. Beddows S, Galpin S, Kazmi SH, et al. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J Med Virol 2003; 70:337-42. (Pubitemid 36638044)
20. Pandit A, Mackay WG, Steel C, van Loon AM, Schuurman R. HIV-1 drug resistance genotyping quality assessment: results of the ENVA7 Genotyping Proficiency Programme. J Clin Virol 2008; 43:401-6.